Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | BIRC5 | O15392 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE9A | O76083 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11449584 | 0.83 | MAPT (0.58) | ATMMAPTPIM1KDM4EHPGD | |
| SCHEMBL10709427 | 0.81 | MET (0.48) | ATMMAPTPIM1KDM4EALDH1A1 | |
| SCHEMBL1162742 | 0.79 | PIM1 (0.54) | MAPTPIM1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9524498 | 0.79 | KDM4E (0.43) | ATMMAPTPIM1BIRC5KDM4E | |
| SCHEMBL19416818 | 0.79 | ALDH1A1 (0.55) | ATMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2822668 | 0.78 | KDR (0.47) | ATMMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9356557 | 0.75 | CYP3A4 (0.44) | ATMMAPTKDM4EHPGDMEN1 | |
| SCHEMBL11026081 | 0.75 | PARP1 (0.50) | ATMPIM1BIRC5KDM4EALDH1A1 | |
| SCHEMBL4958212 | 0.74 | ALDH1A1 (0.53) | ATMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5184144 | 0.73 | PIM1 (0.61) | MAPTPIM1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-110248934-B | Heteroaryl PAD4 inhibitors | 帕德罗科治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-109956898-B | Immunomodulator, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-110248934-A | Heteroaryl PAD4 inhibitor | 帕德罗科治疗公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-3510025-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190016681-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2019-01-17 | — | — | US | disclosed |
| US-20190016681-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2019-01-17 | — | — | US | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017118762-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2017-07-13 | — | — | WO | disclosed |
| EP-3190103-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | Rijksuniversiteit Groningen (NL) | 2017-07-12 | — | — | EP | disclosed |
| EP-3190103-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | Rijksuniversiteit Groningen (NL) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016681-A1 | INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | PDCD1, CD274, PDCD1LG2 | ATM 1741/4885MAPT 3038/4885PIM1 54/4885 |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | ATM 1292/4885MAPT 3883/4885PIM1 2219/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | ATM 1292/4885MAPT 3883/4885PIM1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.